361 related articles for article (PubMed ID: 30819827)
1. Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China.
Fang W; Zhao S; Zhang Y; Ma Y; Zhao H; Zhang L
Oncologist; 2019 Feb; 24(Suppl 1):S11-S20. PubMed ID: 30819827
[TBL] [Abstract][Full Text] [Related]
2. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
3. How to assimilate the tsunami of immune checkpoints inhibitors data into clinical practice?
Castelo-Branco L; Aspeslagh S; Kotecki N; Awada A
Curr Opin Oncol; 2019 Sep; 31(5):420-423. PubMed ID: 31335831
[TBL] [Abstract][Full Text] [Related]
4. Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care-A Systematic Review.
Hall ET; Singhal S; Dickerson J; Gabster B; Wong HN; Aslakson RA; Schapira L;
J Pain Symptom Manage; 2019 Jul; 58(1):137-156.e1. PubMed ID: 30905677
[TBL] [Abstract][Full Text] [Related]
5. Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies.
De Mello RA; Lordick F; Muro K; Janjigian YY
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():237-247. PubMed ID: 31099644
[TBL] [Abstract][Full Text] [Related]
6. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer.
Zhao S; Gao G; Li W; Li X; Zhao C; Jiang T; Jia Y; He Y; Li A; Su C; Ren S; Chen X; Zhou C
Lung Cancer; 2019 Apr; 130():10-17. PubMed ID: 30885328
[TBL] [Abstract][Full Text] [Related]
7. Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors.
Centanni M; Moes DJAR; Trocóniz IF; Ciccolini J; van Hasselt JGC
Clin Pharmacokinet; 2019 Jul; 58(7):835-857. PubMed ID: 30815848
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitor combinations: Current efforts and important aspects for success.
Kon E; Benhar I
Drug Resist Updat; 2019 Jul; 45():13-29. PubMed ID: 31382144
[TBL] [Abstract][Full Text] [Related]
9. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
Choi C; Yoo GS; Cho WK; Park HC
World J Gastroenterol; 2019 May; 25(20):2416-2429. PubMed ID: 31171886
[TBL] [Abstract][Full Text] [Related]
10. The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials.
Fujiwara Y; Horita N; Namkoong H; Galsky MD
Eur J Cancer; 2021 Jun; 150():168-178. PubMed ID: 33906099
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China.
Xiong A; Wang J; Zhou C
Front Oncol; 2021; 11():757993. PubMed ID: 34900707
[TBL] [Abstract][Full Text] [Related]
12. Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.
Hotta K; Fujimoto N
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32098830
[TBL] [Abstract][Full Text] [Related]
13. Acquired Resistance to Immune Checkpoint Inhibitors.
Schoenfeld AJ; Hellmann MD
Cancer Cell; 2020 Apr; 37(4):443-455. PubMed ID: 32289269
[TBL] [Abstract][Full Text] [Related]
14. Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors).
Wu Y; Ju Q; Jia K; Yu J; Shi H; Wu H; Jiang M
Int J Cancer; 2018 Jul; 143(1):45-51. PubMed ID: 29424425
[TBL] [Abstract][Full Text] [Related]
15. Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario.
Rossi G; Pezzuto A; Sini C; Tuzi A; Citarella F; McCusker MG; Nigro O; Tanda E; Russo A
Crit Rev Oncol Hematol; 2019 Oct; 142():26-34. PubMed ID: 31352168
[TBL] [Abstract][Full Text] [Related]
16. Recent advances of immunotherapy for biliary tract cancer.
Rizzo A; Ricci AD; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):527-536. PubMed ID: 33215952
[No Abstract] [Full Text] [Related]
17. Immune checkpoint inhibitors in non-small-cell lung cancer: current status and future directions.
Yan YF; Zheng YF; Ming PP; Deng XX; Ge W; Wu YG
Brief Funct Genomics; 2019 Mar; 18(2):147-156. PubMed ID: 30247518
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors: The linchpins of modern immunotherapy.
Wilky BA
Immunol Rev; 2019 Jul; 290(1):6-23. PubMed ID: 31355494
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review.
Pu D; Yin L; Zhou Y; Li W; Huang L; Cai L; Zhou Q
Medicine (Baltimore); 2020 Jan; 99(5):e19013. PubMed ID: 32000444
[TBL] [Abstract][Full Text] [Related]
20. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis.
Nishijima TF; Muss HB; Shachar SS; Moschos SJ
Cancer Treat Rev; 2016 Apr; 45():30-7. PubMed ID: 26946217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]